First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
Breakthrough results in the treatment of a type of heart failure, which is extremely difficult to manage Strong progress in mental health pipeline Good business performance in all areas, despite ongoing impact of COVID-19 In the first half of 2021, Boehringer